Expression of p53 & epidermal growth factor receptor in glioblastoma

被引:7
|
作者
Karnam, Sameera
Kottu, Radhika [1 ]
Chowhan, Amit Kumar
Bodepati, Prasad Chandramouleswara
机构
[1] Sri Venkateswara Inst Med Sci, Dept Pathol, Alipiri Rd, Tirupati 517507, Andhra Pradesh, India
关键词
Epidermal growth factor receptor; glioblastoma; immunohistochemistry; p53; ASTROCYTOMA PROGRESSION; GENE AMPLIFICATION; MULTIFORME; MUTATIONS; PROTEIN; EGFR; HETEROZYGOSITY; CLASSIFICATION; POPULATION; PATHWAYS;
D O I
10.4103/ijmr.IJMR_1179_15
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background & objectives: Glioblastoma (GB) is the most frequent brain tumour, manifesting at any age, with a peak incidence between 45 and 75 years. Primary and secondary GBs constitute relatively distinct disease entities in evolution, in expression profiles and in therapeutic response. Histopathologically, primary and secondary GBs are indistinguishable. The aim of this investigation was to study the immunohistochemical (IHC) expression of p53 and epidermal growth factor receptor (EGFR) in GB with the objective of categorizing the morphological variants of GB into primary and secondary based on the presence of low-grade areas and knowing the variable expression of p53 and EGFR in primary and secondary GB. Methods: A total of 28 patients with GB were studied and categorized into primary and secondary based on the presence of low-grade areas, i.e. discernible astrocytic morphology, gemistocyte and oligodendroglia. Tumours with the presence of combination of the above features or any one of the above features were taken as secondary GB, whereas tumours with highly pleomorphic areas were considered as primary GB. IHC was done on the representative tissue blocks for p53 and EGFR. Results: Majority of the patients were in the fifth and sixth decades of life with a mean age of 46.96 +/- 13 yr with male preponderance (male:female 2.5:1). Mean age of presentation was 48.93 +/- 12 yr in primary and 44.69 +/- 15 yr in secondary GB. All cases of GB were classified into primary (53.57%) and secondary (46.43%) based on morphology. EGFR was more frequently expressed than p53. Based on IHC, 50 per cent of cases were classified into primary, three per cent into secondary and 47 per cent as unclassified. Interpretation & conclusions: Histopathological features, i.e. presence of low-grade areas, may play a role in classifying GB into primary and secondary. EGFR has a pivotal role in gliomagenesis. Combination of p53 and EGFR alone may not be sufficient to clarify GB into primary and secondary.
引用
收藏
页码:738 / 745
页数:8
相关论文
共 50 条
  • [21] Epidermal growth factor receptor and ligand family expression and activity in glioblastoma
    von Achenbach, Caroline
    Weller, Michael
    Szabo, Emese
    JOURNAL OF NEUROCHEMISTRY, 2018, 147 (01) : 99 - 109
  • [22] DNA aneuploidy in relation to the combination of analysis of estrogen receptor, progesterone receptor, p53 protein and epidermal growth factor receptor in 498 breast cancers
    Tsutsui, S
    Ohno, S
    Murakami, S
    Hachitanda, Y
    Oda, S
    ONCOLOGY, 2002, 63 (01) : 48 - 55
  • [23] Addiction of lung cancer cells to GOF p53 is promoted by up-regulation of epidermal growth factor receptor through multiple contacts with p53 transactivation domain and promoter
    Vaughan, Catherine A.
    Pearsall, Isabella
    Singh, Shilpa
    Windle, Brad
    Deb, Swati P.
    Grossman, Steven R.
    Yeudall, W. Andrew
    Deb, Sumitra
    ONCOTARGET, 2016, 7 (11) : 12426 - 12446
  • [24] A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma
    Kwatra, Madan M.
    CURRENT CANCER DRUG TARGETS, 2017, 17 (03) : 290 - 296
  • [25] MDM2 and p53 expression in gliomas: A multivariate survival analysis including proliferation markers and epidermal growth factor receptor
    Korkolopoulou, P
    Christodoulou, P
    Kouzelis, K
    Hadjiyannakis, M
    Priftis, A
    Stamoulis, G
    Seretis, A
    ThomasTsagli, E
    BRITISH JOURNAL OF CANCER, 1997, 75 (09) : 1269 - 1278
  • [26] Caveolin-1 expression in diffuse gliomas: correlation with the proliferation index, epidermal growth factor receptor, p53, and 1p/19q status
    Barresi, Valeria
    Buttarelli, Francesca Romana
    Vitarelli, Enrica E.
    Arcella, Antonella
    Antonelli, Manila
    Giangaspero, Felice
    HUMAN PATHOLOGY, 2009, 40 (12) : 1738 - 1746
  • [27] Expression of biomarkers (p53, transforming growth factor alpha, epidermal growth factor receptor, c-erbB-2/neu and the proliferative cell nuclear antigen) in oropharyngeal squamous cell carcinomas
    Ibrahim, SO
    Lillehaug, JR
    Johannessen, AC
    Liavaag, PG
    Nilsen, R
    Vasstrand, EN
    ORAL ONCOLOGY, 1999, 35 (03) : 302 - 313
  • [28] Chromosomes 7,17 polysomies and overexpression of epidermal growth factor receptor and p53 protein in epithelial hyperplastic laryngeal lesions
    Gale, N
    Kambic, V
    Poljak, M
    Cör, A
    Velkavrh, D
    Mlacak, B
    ONCOLOGY, 2000, 58 (02) : 117 - 125
  • [29] Epidermal growth factor receptor and p53 expression in T1-T2 glottic cancer involving the anterior or posterior commissure
    Rucci, L
    Bocciolini, C
    Franchi, A
    Ferlito, A
    Casucci, A
    ACTA OTO-LARYNGOLOGICA, 2004, 124 (01) : 102 - 106
  • [30] Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression
    Ohsaki, Y
    Tanno, S
    Fujita, Y
    Toyoshima, E
    Fujiuchi, S
    Nishigaki, Y
    Ishida, S
    Nagase, A
    Miyokawa, N
    Hirata, S
    Kikuchi, K
    ONCOLOGY REPORTS, 2000, 7 (03) : 603 - 607